



Update January, 2021



Curated by Peter Lansberg,  
a Dutch lipidologist and educator, and  
reviewed by prof. Philip Barter, Past President of the  
International Atherosclerosis Society.

The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

© P.J. Lansberg

## Statin publications January 2021

### Add on treatments

1. Arafa MF, Alshaikh RA, Abdelquader MM, El Maghraby GM. Co-processing of Atorvastatin and Ezetimibe for Enhanced Dissolution Rate: In Vitro and In Vivo Correlation. *AAPS PharmSciTech* 2021; 22:59. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33517486>
2. Ambrosy AP, Malik UI, Thomas RC *et al.* Rationale and Design of the Pragmatic Randomized Trial of Icosapent Ethyl for High Cardiovascular Risk Adults (MITIGATE). *Am Heart J* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516752>
3. Nicholls SJ, Lincoff AM, Bays HE *et al.* Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance. *Am Heart J* 2020. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33470195>

4. Rubino J, MacDougall DE, Sterling LR *et al.* Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial. Atherosclerosis 2020. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514449>
5. Susekov AV, Korol LA, Watts GF. Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance. Cardiovasc Drugs Ther 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502687>
6. Schwartz GG, Steg PG, Bhatt DL *et al.* Clinical Efficacy and Safety of Alirocumab after Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial. Circulation 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33438437>
7. Ray KK. Changing the paradigm for post-MI cholesterol lowering from intensive statin monotherapy towards intensive lipid-lowering regimens and individualized care. Eur Heart J 2021; 42:253-256. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33454778>
8. Blanc JF, Khemissa F, Bronowicki JP *et al.* Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis. Hepatol Int 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33420951>
9. Majeed ML, Ghafil FA, Fatima G *et al.* Anti-Atherosclerotic and Anti-Inflammatory Effects of Curcumin on Hypercholesterolemic Male Rabbits. Indian J Clin Biochem 2021; 36:74-80. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505130>
10. Jenkins DJA, Spence JD, Giovannucci EL *et al.* Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment: JACC Focus Seminar. J Am Coll Cardiol 2021; 77:423-436. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509399>
11. Thomas AB, Choudhary DC, Raje A, Nagrik SS. Pharmacokinetics and Pharmacodynamic Herb-Drug Interaction of Piperine with Atorvastatin in Rats. Journal of chromatographic science 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33434916>
12. Khan MS, Ishaq M, Ayub MT *et al.* The Novelty of Icosapent Ethyl in the Management of Hypertriglyceridemia and Alleviating Cardiovascular Risk. Journal of lipids 2021; 2021:6696915. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505729>
13. Ajima H, Kai Y, Fujimaki J *et al.* Effects of fenofibrate and its combination with lovastatin on the expression of genes involved in skeletal muscle atrophy, including FoxO1 and its targets. The Journal of toxicological sciences 2021; 46:11-24. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33408297>
14. Jatem E, Lima J, Montoro B *et al.* Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome. Kidney international reports 2021; 6:101-109. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33426389>

15. Zhang Q, Wang L, Wang J. Clinical study of atorvastatin combined with milrinone in the treatment of chronic heart failure. Minerva medica 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33438377>
16. Okada T, Miyoshi T, Doi M *et al.* Secular Decreasing Trend in Plasma Eicosapentaenoic and Docosahexaenoic Acids among Patients with Acute Coronary Syndrome from 2011 to 2019: A Single Center Descriptive Study. Nutrients 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477264>
17. Skotnicki M, Jadach B, Skotnicka A *et al.* Physicochemical Characterization of a Co-Amorphous Atorvastatin-Irbesartan System with a Potential Application in Fixed-Dose Combination Therapy. Pharmaceutics 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477672>
18. Marková I, Malínská H, Hüttl M *et al.* The combination of atorvastatin with silymarin enhances hypolipidemic, antioxidant and anti-inflammatory effects in a rat model of metabolic syndrome. Physiological research / Academia Scientiarum Bohemoslovaca 2021; 70. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33453720>

## Adherence

1. Mahtta D, Lee MT, Ramsey DJ *et al.* Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans with premaTure Atherosclerosis) Registry7. Cardiovasc Drugs Ther 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33400053>
2. Larsen JV, Martinsen MH, Mortensen MB *et al.* Contemporary lipid clinic and achievements in low-density lipoprotein-cholesterol reductions in very high-risk patients. Dan Med J 2020; 68. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463509>
3. Tarn DM, Barrientos M, Pletcher MJ *et al.* Perceptions of Patients with Primary Nonadherence to Statin Medications. Journal of the American Board of Family Medicine : JABFM 2021; 34:123-131. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33452090>
4. Cornwell S, Curry K. Provider Adherence to Prescribing Guidelines for Statin Therapy. J Dr Nurs Pract 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468610>
5. Majd Z, Mohan A, Paranjpe R, Abughosh SM. Identifying adherent patients to newly initiated statins using previous adherence to chronic medications. Journal of managed care & specialty pharmacy 2021; 27:186-197. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506725>
6. Robinson JG. The neuropsychology of statin intolerance. Nat Rev Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33408360>
7. Mohan A, Vadhariya A, Majd Z *et al.* Impact of a motivational interviewing intervention targeting statins on adherence to concurrent hypertension or diabetes

medications. Patient education and

counseling 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33402279>

8. Chinwong S, Doungsong K, Channaina P *et al.* Association between medication adherence and cardiovascular outcomes among acute coronary syndrome patients. Research in social & administrative pharmacy : RSAP 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455883>

## Atherosclerosis & Imaging

1. Khazaei M, Khosravi M, Mazaheri S *et al.* The effect of atorvastatin on the common carotid artery intima-media thickness in patients with ischemic stroke. Acta clinica Croatica 2020; 59:223-226. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456108>
2. Li X, Gu F, Ding J *et al.* The predictors and prognosis for unexpected reocclusion after mechanical thrombectomy: a meta-analysis. Annals of translational medicine 2020; 8:1566. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33437765>
3. Xian JZ, Lu M, Fong F *et al.* Statin Effects on Vascular Calcification: Microarchitectural Changes in Aortic Calcium Deposits in Aged Hyperlipidemic Mice. Arterioscler Thromb Vasc Biol 2021:Atvbaha120315737. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472400>
4. Béland-Bonenfant S, Paquette M, Fantino M *et al.* Montreal-FH-SCORE Predicts Coronary Artery Calcium Score in Patients With Familial Hypercholesterolemia. CJC Open 2021; 3:41-47. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458631>
5. Drouin-Chartier JP, Tremblay AJ, Godbout D *et al.* Correlates of Coronary Artery Calcification Prevalence and Severity in Patients With Heterozygous Familial Hypercholesterolemia. CJC Open 2021; 3:62-70. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458634>
6. Chao CJ, Lakshmanan S, Ceponiene I *et al.* New carotid plaque, but not the progression of intima-media thickness, predicts the progression of high-risk coronary plaque. Coronary artery disease 2021; Publish Ahead of Print. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33417340>
7. Lai R, Ju J, Lin Q, Xu H. Coronary Artery Calcification Under Statin Therapy and Its Effect on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. Frontiers in cardiovascular medicine 2020; 7:600497. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33426001>
8. Sun J, Lepor NE, Cantón G *et al.* Serial magnetic resonance imaging detects a rapid reduction in plaque lipid content under PCSK9 inhibition with alirocumab. The international journal of cardiovascular imaging 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33392875>

9. Uematsu M, Nakamura T, Horikoshi T *et al.* Echolucency of carotid plaque is useful for selecting high-risk patients with chronic coronary artery disease who benefit from intensive lipid-lowering therapy. J Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500186>
10. Venkataraman P, Kawakami H, Huynh Q *et al.* Cost-Effectiveness of Coronary Artery Calcium Scoring in People With a Family History of Coronary Disease. JACC. Cardiovascular imaging 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33454262>
11. Fakheri RJ. Coronary Artery Calcium Scores I. Mayo Clinic proceedings 2021; 96:261. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33413826>
12. Langland JT. Coronary Artery Calcium Scores II. Mayo Clinic proceedings 2021; 96:262. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33413827>
13. Orringer CE, Maki KC. In Reply-Coronary Artery Calcium Scores I and II. Mayo Clinic proceedings 2021; 96:262-263. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33413828>

### Atorvastatin/Rosuvastatin

1. Russell LE, DeGorter MK, Ho RH *et al.* Mouse NTCP-Mediated Rosuvastatin Uptake In Vitro and in Slc10a1-Deficient Mice. The AAPS journal 2021; 23:17. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33404849>
2. Arafa MF, Alshaikh RA, Abdelquader MM, El Maghraby GM. Co-processing of Atorvastatin and Ezetimibe for Enhanced Dissolution Rate: In Vitro and In Vivo Correlation. AAPS PharmSciTech 2021; 22:59. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33517486>
3. Liu Q, Xu J, Liao K, Tang N. Oral Bioavailability Improvement of Tailored Rosuvastatin Loaded Niosomal Nanocarriers to Manage Ischemic Heart Disease: Optimization, Ex Vivo and In Vivo Studies. AAPS PharmSciTech 2021; 22:58. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502651>
4. Roan JN, Lin WH, Tsai MT *et al.* Rosuvastatin Failed to Improve Arteriovenous Fistula Patency for Hemodialysis in Diabetic Patients - A Randomized Clinical Trial. Acta Cardiologica Sinica 2021; 37:18-29. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488024>
5. Khazaei M, Khosravi M, Mazaheri S *et al.* The effect of atorvastatin on the common carotid artery intima-media thickness in patients with ischemic stroke. Acta clinica Croatica 2020; 59:223-226. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456108>
6. Guo D, Meng Z, He F *et al.* Infection-Induced Rhabdomyolysis in an Elderly Patient on Stable Rosuvastatin Therapy: A Case Report and Review of the Literature. American journal of therapeutics 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33443867>

7. Famularo G, Sarrecchia C. Atorvastatin-Associated Gynecomastia. The Annals of pharmacotherapy 2021;1060028021988994. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472378>
8. Rubino J, MacDougall DE, Sterling LR *et al.* Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial. Atherosclerosis 2020. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514449>
9. Werida R, Khairat I, Khedr NF. Effect of atorvastatin versus rosuvastatin on inflammatory biomarkers and LV function in type 2 diabetic patients with dyslipidemia. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2021; 135:111179. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33401219>
10. Bergeron S, Barus R, Leboullenger C *et al.* Beneficial effects of atorvastatin on sex-specific cognitive impairment induced by a cerebral microhaemorrhage in a murine model. Br J Pharmacol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502755>
11. Chen A, Chen Z, Zhou Y *et al.* Rosuvastatin protects against coronary microembolization-induced cardiac injury via inhibiting NLRP3 inflammasome activation. Cell death & disease 2021; 12:78. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33436548>
12. Kanukula R, Salam A, Rodgers A, Kamel B. Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults. Clinical pharmacokinetics 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33428168>
13. Shawish MI, Bagheri B, Musini VM *et al.* Effect of atorvastatin on testosterone levels. The Cochrane database of systematic reviews 2021; 1:Cd013211. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482034>
14. Umrani S, Jamshed W, Rizwan A. Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Markers in Acute Coronary Syndrome. Cureus 2020; 12:e11760. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33409009>
15. Al-Doaiss A, Jarrar Y, Shati A *et al.* Renal Alterations Induced by Chronic Exposure to Therapeutic Doses of Antihypercholesteremic Atorvastatin. Endocrine, metabolic & immune disorders drug targets 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33413070>
16. Lian Z, Song JX, Yu SR *et al.* Therapeutic targets of rosuvastatin on heart failure and associated biological mechanisms: A study of network pharmacology and experimental validation. Eur J Pharmacol 2021; 895:173888. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493484>
17. Shirakawa T, Fujisue K, Nakamura S *et al.* Dose-Dependent Inhibitory Effect of Rosuvastatin in Japanese Patients with Acute Myocardial Infarction on Serum Concentration of Matrix Metalloproteinases-INVITATION Trial. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33408315>

18. Thomas AB, Choudhary DC, Raje A, Nagrik SS. Pharmacokinetics and Pharmacodynamic Herb-Drug Interaction of Piperine with Atorvastatin in Rats. Journal of chromatographic science 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33434916>
19. Fernandez KA, Allen P, Campbell M *et al.* Atorvastatin is associated with reduced cisplatin-induced hearing loss. J Clin Invest 2021; 131. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33393488>
20. Mansour BS, Salem NA, Kader GA *et al.* Protective effect of Rosuvastatin on Azithromycin induced cardiotoxicity in a rat model. Life sciences 2021; 269:119099. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476632>
21. Zhang Q, Wang L, Wang J. Clinical study of atorvastatin combined with milrinone in the treatment of chronic heart failure. Minerva medica 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33438377>
22. Velarde GP, Choudhary N, Bravo-Jaimes K *et al.* Effect of atorvastatin on lipogenic, inflammatory and thrombogenic markers in women with the metabolic syndrome. Nutrition, metabolism, and cardiovascular diseases : NMCD 2020. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485731>
23. Skotnicki M, Jadach B, Skotnicka A *et al.* Physicochemical Characterization of a Co-Amorphous Atorvastatin-Irbesartan System with a Potential Application in Fixed-Dose Combination Therapy. Pharmaceutics 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477672>
24. Marková I, Malínská H, Hüttl M *et al.* The combination of atorvastatin with silymarin enhances hypolipidemic, antioxidant and anti-inflammatory effects in a rat model of metabolic syndrome. Physiological research / Academia Scientiarum Bohemoslovaca 2021; 70. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33453720>
25. Christiansen LB, Dohlmann TL, Ludvigsen TP *et al.* Atorvastatin impairs liver mitochondrial function in obese Göttingen Minipigs but heart and skeletal muscle are not affected. Scientific reports 2021; 11:2167. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500513>
26. Mysore Y, Del Amo EM, Loukovaara S *et al.* Statins for the prevention of proliferative vitreoretinopathy: cellular responses in cultured cells and clinical statin concentrations in the vitreous. Scientific reports 2021; 11:980. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33441813>
27. Yang Y, Yang LY, Salayandia VM *et al.* Treatment with Atorvastatin During Vascular Remodeling Promotes Pericyte-Mediated Blood-Brain Barrier Maturation Following Ischemic Stroke. Translational stroke research 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33423214>

**Basic science**



1. Russell LE, DeGorter MK, Ho RH *et al.* Mouse NTCP-Mediated Rosuvastatin Uptake In Vitro and in Slc10a1-Deficient Mice. The AAPS journal 2021; 23:17. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33404849>
2. Arafa MF, Alshaikh RA, Abdelquader MM, El Maghraby GM. Co-processing of Atorvastatin and Ezetimibe for Enhanced Dissolution Rate: In Vitro and In Vivo Correlation. AAPS PharmSciTech 2021; 22:59. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33517486>
3. Liu Q, Xu J, Liao K, Tang N. Oral Bioavailability Improvement of Tailored Rosuvastatin Loaded Niosomal Nanocarriers to Manage Ischemic Heart Disease: Optimization, Ex Vivo and In Vivo Studies. AAPS PharmSciTech 2021; 22:58. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502651>
4. Wang K, Yu C, Liu Y *et al.* Enhanced Antiatherosclerotic Efficacy of Statin-Loaded Reconstituted High-Density Lipoprotein via Ganglioside GM1 Modification. ACS biomaterials science & engineering 2018; 4:952-962. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33418777>
5. Zhou T, Moriyama Y, Ayukawa Y *et al.* Injectable Porous Bioresorbable Composite Containing Fluvastatin for Bone Augmentation. ACS biomaterials science & engineering 2019; 5:5422-5429. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464062>
6. Ryngajło M, Boruta T, Bizukojć M. Complete genome sequence of lovastatin producer *Aspergillus terreus* ATCC 20542 and evaluation of genomic diversity among *A. terreus* strains. Applied microbiology and biotechnology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33515286>
7. Houshmand G, Pourasghar M, Shiran M *et al.* Simvastatin prevents morphine antinociceptive tolerance and withdrawal symptoms through antioxidative effect and nitric oxide pathway in mice. Behavioural brain research 2021; 402:113104. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33417990>
8. Kumar GA, Chattopadhyay A. Membrane cholesterol regulates endocytosis and trafficking of the serotonin(1A) receptor: Insights from acute cholesterol depletion. Biochimica et biophysica acta. Molecular and cell biology of lipids 2021; 1866:158882. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33429076>
9. Gutierrez LLP, Marques CV, Scmazzon SP *et al.* A-family anti-inflammatory cyclopentenone prostaglandins: A novel class of non-statin inhibitors of HMG-CoA reductase. Biochimie 2021; 182:37-50. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33412161>
10. Rus I, Tertiş M, Barbălată C *et al.* An Electrochemical Strategy for the Simultaneous Detection of Doxorubicin and Simvastatin for Their Potential Use in the Treatment of Cancer. Biosensors (Basel) 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33401625>



11. Bergeron S, Barus R, Leboullenger C *et al.* Beneficial effects of atorvastatin on sex-specific cognitive impairment induced by a cerebral microhaemorrhage in a murine model. Br J Pharmacol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502755>
12. Maneechotesuwan K, Kasetsinsombat K, Wongkajornsilp A, Barnes PJ. Role of autophagy in regulating interleukin-10 and the responses to corticosteroids and statins in asthma. Clin Exp Allergy 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33423318>
13. Zhang J, Wang J, Qiao F *et al.* Polymeric non-spherical coarse microparticles fabricated by double emulsion-solvent evaporation for simvastatin delivery. Colloids and surfaces. B, Biointerfaces 2021; 199:111560. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33429284>
14. Al-Doaiss A, Jarrar Y, Shati A *et al.* Renal Alterations Induced by Chronic Exposure to Therapeutic Doses of Antihypercholesteremic Atorvastatin. Endocrine, metabolic & immune disorders drug targets 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33413070>
15. Lian Z, Song JX, Yu SR *et al.* Therapeutic targets of rosuvastatin on heart failure and associated biological mechanisms: A study of network pharmacology and experimental validation. Eur J Pharmacol 2021; 895:173888. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493484>
16. Natalia ML, Patricia GL. Statins as adjuvants in the treatment of ovarian cancer: Controversy and misunderstanding. Eur J Pharmacol 2021; 896:173915. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513335>
17. Sithole MN, Marais S, Maree SM *et al.* Development and characterization of nano-emulsions and nano-emulgels for transdermal delivery of statins. Expert opinion on drug delivery 2021:1-13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33393386>
18. Koike A, Tsujinaka K, Fujimori K. Statins attenuate antiviral IFN- $\beta$  and ISG expression via inhibition of IRF3 and JAK/STAT signaling in poly(I:C)-treated hyperlipidemic mice and macrophages. The FEBS journal 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33452755>
19. Majeed ML, Ghafil FA, Fatima G *et al.* Anti-Atherosclerotic and Anti-Inflammatory Effects of Curcumin on Hypercholesterolemic Male Rabbits. Indian J Clin Biochem 2021; 36:74-80. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505130>
20. Rezvanian M, Ng SF, Alavi T, Ahmad W. In-vivo evaluation of Alginate-Pectin hydrogel film loaded with Simvastatin for diabetic wound healing in Streptozotocin-induced diabetic rats. International journal of biological macromolecules 2021; 171:308-319. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33421467>
21. Avram VF, Chamkha I, Åsander-Frostner E *et al.* Cell-Permeable Succinate Rescues Mitochondrial Respiration in Cellular Models of Statin Toxicity. Int J Mol Sci 2021; 22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33401621>

22. Zabroski IO, Nugent MA. Lipid Raft Association Stabilizes VEGF Receptor 2 in Endothelial Cells. Int J Mol Sci 2021;  
22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466887>
23. Katsuki S, Koga JI, Matoba T *et al.* Nanoparticle-Mediated Delivery of Pitavastatin to Monocytes/Macrophages Inhibits Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Apoe(−/−) Mice. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455994>
24. Wei G, Xue L, Zhu Y *et al.* Differences in susceptibility of HT-29 and A549 cells to statin-induced toxicity: An investigation using high content screening. Journal of biochemical and molecular toxicology 2021:e22699. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33398916>
25. Tang B, Kang P, Zhu L *et al.* Simvastatin protects heart function and myocardial energy metabolism in pulmonary arterial hypertension induced right heart failure. J Bioenerg Biomembr 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33394312>
26. Mollazadeh H, Tavana E, Fanni G *et al.* Effects of statins on mitochondrial pathways. Journal of cachexia, sarcopenia and muscle 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511728>
27. Thomas AB, Choudhary DC, Raje A, Nagrik SS. Pharmacokinetics and Pharmacodynamic Herb-Drug Interaction of Piperine with Atorvastatin in Rats. Journal of chromatographic science 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33434916>
28. Meyer N, Brodowski L, Richter K *et al.* Pravastatin Promotes Endothelial Colony-Forming Cell Function, Angiogenic Signaling and Protein Expression In Vitro. Journal of clinical medicine 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33419165>
29. Yu WY, Hill ST, Chan ER *et al.* Computational drug repositioning identifies statins as a modifier of prognostic genetic expression signatures and metastatic behavior in melanoma. The Journal of investigative dermatology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33417917>
30. Mohamadin AM, Elberry AA, Abdel Gawad HS *et al.* Corrigendum to "Protective Effects of Simvastatin, a Lipid Lowering Agent, Against Oxidative Damage in Experimental Diabetic Rats". Journal of lipids 2020;  
2020:4536827. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33414967>
31. Teisseyre A, Uryga A, Michalak K. Statins as inhibitors of voltage-gated potassium channels Kv1.3 in cancer cells. J Mol Struct 2021;  
1230:129905. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33437096>
32. Ye S, Matthan NR, Lamon-Fava S *et al.* Colon Transcriptome is Modified by a Dietary Pattern/Atorvastatin Interaction in the Ossabaw Pig. The Journal of nutritional biochemistry 2021:108570. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33429036>

33. Ajima H, Kai Y, Fujimaki J *et al.* Effects of fenofibrate and its combination with lovastatin on the expression of genes involved in skeletal muscle atrophy, including FoxO1 and its targets. The Journal of toxicological sciences 2021; 46:11-24. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33408297>
34. Mansour BS, Salem NA, Kader GA *et al.* Protective effect of Rosuvastatin on Azithromycin induced cardiotoxicity in a rat model. Life sciences 2021; 269:119099. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476632>
35. Lee J, Kreutzberger AJB, Odongo L *et al.* Ebola virus glycoprotein interacts with cholesterol to enhance membrane fusion and cell entry. Nat Struct Mol Biol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462517>
36. Shabanzadeh AP, Charish J, Tassew NG *et al.* Cholesterol synthesis inhibition promotes axonal regeneration in the injured central nervous system. Neurobiology of disease 2021:105259. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33434618>
37. Wu YR, Li L, Sun XC *et al.* Diallyl disulfide improves lipid metabolism by inhibiting PCSK9 expression and increasing LDL uptake via PI3K/Akt-SREBP2 pathway in HepG2 cells. Nutrition, metabolism, and cardiovascular diseases : NMCD 2021; 31:322-332. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500108>
38. Van Ly D, Wang D, Conway RM *et al.* Lipid-Producing Ciliochoroidal Melanoma with Expression of HMG-CoA Reductase. Ocul Oncol Pathol 2020; 6:416-421. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33447591>
39. Taymouri S, Ahmadi Z, Mirian M, Tavakoli N. Simvastatin nanosuspensions prepared using a combination of pH-sensitive and timed-release approaches for potential treatment of colorectal cancer. Pharmaceutical development and technology 2021:1-14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33430677>
40. Salem HF, Kharshoum RM, Abou-Taleb HA *et al.* Fabrication and Appraisal of Simvastatin via Tailored Niosomal Nanovesicles for Transdermal Delivery Enhancement: In Vitro and In Vivo Assessment. Pharmaceutics 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494472>
41. Skotnicki M, Jadach B, Skotnicka A *et al.* Physicochemical Characterization of a Co-Amorphous Atorvastatin-Irbesartan System with a Potential Application in Fixed-Dose Combination Therapy. Pharmaceutics 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477672>
42. Marková I, Malínská H, Hüttl M *et al.* The combination of atorvastatin with silymarin enhances hypolipidemic, antioxidant and anti-inflammatory effects in a rat model of metabolic syndrome. Physiological research / Academia Scientiarum Bohemoslovaca 2021; 70. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33453720>
43. Faris TM, Harisa GI, Alanazi FK *et al.* Developed simvastatin chitosan nanoparticles co-crosslinked with tripolyphosphate and chondroitin sulfate for ASGPR-mediated targeted HCC delivery with enhanced oral bioavailability. Saudi pharmaceutical journal : SPJ :

- the official publication of the Saudi Pharmaceutical Society 2020; 28:1851-1867. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33424274>
44. Christiansen LB, Dohlmann TL, Ludvigsen TP *et al.* Atorvastatin impairs liver mitochondrial function in obese Göttingen Minipigs but heart and skeletal muscle are not affected. Scientific reports 2021; 11:2167. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500513>
  45. Liu W, Wang M, Shen L *et al.* SHP2-mediated mitophagy boosted by lovastatin in neuronal cells alleviates parkinsonism in mice. Signal Transduct Target Ther 2021; 6:34. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514686>
  46. Li H, Wang Y, Liu J *et al.* Endothelial Klf2-Foxp1-TGF $\beta$  signal mediates the inhibitory effects of simvastatin on maladaptive cardiac remodeling. Theranostics 2021; 11:1609-1625. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33408770>
  47. Yang Y, Yang LY, Salayandia VM *et al.* Treatment with Atorvastatin During Vascular Remodeling Promotes Pericyte-Mediated Blood-Brain Barrier Maturation Following Ischemic Stroke. Translational stroke research 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33423214>

## Cancer

1. Rus I, Tertiş M, Barbălată C *et al.* An Electrochemical Strategy for the Simultaneous Detection of Doxorubicin and Simvastatin for Their Potential Use in the Treatment of Cancer. Biosensors (Basel) 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33401625>
2. Yang SY, Wang CC, Chen KD *et al.* Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma. BMC Cancer 2021; 21:70. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33446127>
3. Kura B, Kalocayova B, Szeiffova Bacova B *et al.* The effect of selected drugs on the mitigation of myocardial injury caused by gamma radiation. Canadian journal of physiology and pharmacology 2021:1-9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33438486>
4. Shi Y, Wahle E, Du Q *et al.* Associations between Statin/Omega3 Usage and MRI-Based Radiomics Signatures in Prostate Cancer. Diagnostics (Basel, Switzerland) 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33430275>
5. Wang J, Li X. Impact of statin use on the risk and prognosis of hepatocellular carcinoma: a meta-analysis. European journal of gastroenterology & hepatology 2021; Publish Ahead of Print. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33405428>
6. Natalia ML, Patricia GL. Statins as adjuvants in the treatment of ovarian cancer: Controversy and misunderstanding. Eur J Pharmacol 2021; 896:173915. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513335>

7. Hamilton RJ, Ding K, Crook JM *et al.* The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy. European urology 2020. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33390282>
8. Blanc JF, Khemissa F, Bronowicki JP *et al.* Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis. Hepatol Int 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33420951>
9. Abdel-Qadir H, Bobrowski D, Zhou L *et al.* Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity Score–Matched Cohort Study. J Am Heart Assoc 2021:e018393. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33401953>
10. Fernandez KA, Allen P, Campbell M *et al.* Atorvastatin is associated with reduced cisplatin-induced hearing loss. J Clin Invest 2021; 131. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33393488>
11. Yu WY, Hill ST, Chan ER *et al.* Computational drug repositioning identifies statins as a modifier of prognostic genetic expression signatures and metastatic behavior in melanoma. The Journal of investigative dermatology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33417917>
12. Teisseyre A, Uryga A, Michalak K. Statins as inhibitors of voltage-gated potassium channels Kv1.3 in cancer cells. J Mol Struct 2021; 1230:129905. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33437096>
13. Ye S, Matthan NR, Lamon-Fava S *et al.* Colon Transcriptome is Modified by a Dietary Pattern/Atorvastatin Interaction in the Ossabaw Pig. The Journal of nutritional biochemistry 2021:108570. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33429036>
14. Ferro M, Marchioni M, Lucarelli G *et al.* Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicentre study. Minerva urologica e nefrologica = The Italian journal of urology and nephrology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33439571>
15. Van Ly D, Wang D, Conway RM *et al.* Lipid-Producing Ciliochoroidal Melanoma with Expression of HMG-CoA Reductase. Ocul Oncol Pathol 2020; 6:416-421. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33447591>
16. Taymouri S, Ahmadi Z, Mirian M, Tavakoli N. Simvastatin nanosuspensions prepared using a combination of pH-sensitive and timed-release approaches for potential treatment of colorectal cancer. Pharmaceutical development and technology 2021:1-14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33430677>
17. Atkins KM, Bitterman DS, Chaunzwa TL *et al.* Statin Use, Heart Radiation Dose, and Survival in Locally Advanced Lung Cancer. Pract Radiat Oncol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476841>

18. Faris TM, Harisa GI, Alanazi FK *et al.* Developed simvastatin chitosan nanoparticles co-crosslinked with tripolyphosphate and chondroitin sulfate for ASGPR-mediated targeted HCC delivery with enhanced oral bioavailability. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society 2020; 28:1851-1867. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33424274>
19. Huynh LM, Keit E, Schuller AA *et al.* Impact of statin use on overall and time to biochemical failure following radical prostatectomy or radiation therapy. World J Urol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502557>

## Children

1. Futema M, Ramaswami U, Tichy L *et al.* Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis 2021; 319:108-117. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508743>

## Cost-effectiveness

1. Sun J, Lepor NE, Cantón G *et al.* Serial magnetic resonance imaging detects a rapid reduction in plaque lipid content under PCSK9 inhibition with alirocumab. The international journal of cardiovascular imaging 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33392875>
2. Kotsopoulos N, Connolly MP, Li J. Estimating the public economic consequences of cardiovascular disease-attributable events and evolocumab treatment in Australia. Journal of medical economics 2021; 24:123-130. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464137>
3. Venkataraman P, Kawakami H, Huynh Q *et al.* Cost-Effectiveness of Coronary Artery Calcium Scoring in People With a Family History of Coronary Disease. JACC. Cardiovascular imaging 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33454262>

## CVD

1. Jarrah MI, Ababneh MJ, Tawalbeh LI *et al.* Statin eligibility based on the ACC/AHA guidelines among Middle Eastern patients with diabetes mellitus presenting with acute myocardial infarction. Annals of medicine and surgery (2012) 2021; 61:148-154. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33425348>

2. Li X, Gu F, Ding J *et al.* The predictors and prognosis for unexpected reocclusion after mechanical thrombectomy: a meta-analysis. Annals of translational medicine 2020; 8:1566. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33437765>
3. Werida R, Khairat I, Khedr NF. Effect of atorvastatin versus rosuvastatin on inflammatory biomarkers and LV function in type 2 diabetic patients with dyslipidemia. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2021; 135:111179. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33401219>
4. Mahtta D, Lee MT, Ramsey DJ *et al.* Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans with premaTure AtheroscLerosis) Registry7. Cardiovasc Drugs Ther 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33400053>
5. Chen A, Chen Z, Zhou Y *et al.* Rosuvastatin protects against coronary microembolization-induced cardiac injury via inhibiting NLRP3 inflammasome activation. Cell death & disease 2021; 12:78. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33436548>
6. Schwartz GG, Steg PG, Bhatt DL *et al.* Clinical Efficacy and Safety of Alirocumab after Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial. Circulation 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33438437>
7. Nicolau JC, Furtado RHM, Dalçóquio TF *et al.* Factors associated with actively working in the very long-term following acute coronary syndrome. Clinics (Sao Paulo, Brazil) 2021; 76:e2553. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33503196>
8. Lian Z, Song JX, Yu SR *et al.* Therapeutic targets of rosuvastatin on heart failure and associated biological mechanisms: A study of network pharmacology and experimental validation. Eur J Pharmacol 2021; 895:173888. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33493484>
9. Abdel-Qadir H, Bobrowski D, Zhou L *et al.* Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity Score-Matched Cohort Study. J Am Heart Assoc 2021:e018393. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33401953>
10. Omote K, Yokota I, Nagai T *et al.* High-Density Lipoprotein Cholesterol and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Statins: An Observation from the REAL-CAD Study. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33431716>
11. Shirakawa T, Fujisue K, Nakamura S *et al.* Dose-Dependent Inhibitory Effect of Rosuvastatin in Japanese Patients with Acute Myocardial Infarction on Serum



- Concentration of Matrix Metalloproteinases-INVITATION Trial. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33408315>
12. Tang B, Kang P, Zhu L *et al*. Simvastatin protects heart function and myocardial energy metabolism in pulmonary arterial hypertension induced right heart failure. J Bioenerg Biomembr 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33394312>
  13. Wongsalap Y, Kengkla K, Poolpun D, Saokaew S. Trends in optimal medical therapy at discharge and clinical outcomes in patients with acute coronary syndrome in Thailand. J Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455848>
  14. Gard A, Lindahl B, Hadziosmanovic N, Baron T. Treatment and Prognosis of Myocardial Infarction Outside Cardiology Departments. Journal of clinical medicine 2020; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33396830>
  15. Hadaegh F, Asgari S, Moosaie F *et al*. The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study. Journal of translational medicine 2021; 19:25. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33407576>
  16. Zhang Q, Wang L, Wang J. Clinical study of atorvastatin combined with milrinone in the treatment of chronic heart failure. Minerva medica 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33438377>
  17. Okada T, Miyoshi T, Doi M *et al*. Secular Decreasing Trend in Plasma Eicosapentaenoic and Docosahexaenoic Acids among Patients with Acute Coronary Syndrome from 2011 to 2019: A Single Center Descriptive Study. Nutrients 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477264>
  18. Brown RE, Welsh P, Logue J. Systematic review of clinical guidelines for lipid lowering in the secondary prevention of cardiovascular disease events. Open heart 2020; 7. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33443127>
  19. Osborne J, Friedman K, Runeckles K *et al*. Comparison Between Currently Recommended Long-Term Medical Management of Coronary Artery Aneurysms After Kawasaki Disease and Actual Reported Management in the Last Two Decades. Pediatr Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33439285>
  20. Pastori D, Baratta F, Di Rocco A *et al*. Statin use and mortality in atrial fibrillation: A systematic review and meta-analysis of 100,287 patients. Pharmacol Res 2021;105418. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33450384>
  21. Jung HH. Statin use and outcome risks according to predicted CVD risk in Korea: A retrospective cohort study. PLoS One 2021; 16:e0245609. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33450746>
  22. Chinwong S, Doungsong K, Channaina P *et al*. Association between medication adherence and cardiovascular outcomes among acute coronary syndrome patients. Research in social & administrative pharmacy : RSAP 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455883>

23. Li H, Wang Y, Liu J *et al.* Endothelial Klf2-Foxp1-TGF $\beta$  signal mediates the inhibitory effects of simvastatin on maladaptive cardiac remodeling. Theranostics 2021; 11:1609-1625. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33408770>

## Endothelium/inflammation

1. Kaiser H, Kvist-Hansen A, Krakauer M *et al.* Statin Therapy and Vascular Inflammation Detected by Positron Emission Tomography/Computed Tomography in Patients with Psoriasis. Acta Derm Venereol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33491097>
2. Chen A, Chen Z, Zhou Y *et al.* Rosuvastatin protects against coronary microembolization-induced cardiac injury via inhibiting NLRP3 inflammasome activation. Cell death & disease 2021; 12:78. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33436548>
3. Libby P. Inflammation in Atherosclerosis-No Longer a Theory. Clinical chemistry 2021; 67:131-142. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33393629>
4. Maneechotesuwan K, Kasetsinsombat K, Wongkajornsilp A, Barnes PJ. Role of autophagy in regulating interleukin-10 and the responses to corticosteroids and statins in asthma. Clin Exp Allergy 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33423318>
5. Umrani S, Jamshed W, Rizwan A. Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Markers in Acute Coronary Syndrome. Cureus 2020; 12:e11760. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33409009>
6. Adamstein NH, MacFadyen JG, Rose LM *et al.* The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. Eur Heart J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33417682>
7. Koike A, Tsujinaka K, Fujimori K. Statins attenuate antiviral IFN- $\beta$  and ISG expression via inhibition of IRF3 and JAK/STAT signaling in poly(I:C)-treated hyperlipidemic mice and macrophages. The FEBS journal 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33452755>

## Ethnicity

1. Jarrah MI, Ababneh MJ, Tawalbeh LI *et al.* Statin eligibility based on the ACC/AHA guidelines among Middle Eastern patients with diabetes mellitus presenting with acute myocardial infarction. Annals of medicine and surgery (2012) 2021; 61:148-154. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33425348>
2. Yang SY, Wang CC, Chen KD *et al.* Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma. BMC Cancer 2021; 21:70. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33446127>

3. Chen CY, Wu WT, Wang YL, Liao KM. Statins for the Treatment of Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease. Frontiers in pharmacology 2020; 11:613761. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510638>
4. Fang HSA, Gao Q, Lee ML *et al.* LDL-cholesterol change and goal attainment following statin intensity titration among Asians in primary care: a retrospective cohort study. Lipids Health Dis 2021; 20:2. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33407522>
5. Kim JB, Song WH, Park JS *et al.* A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia. PLoS One 2021; 16:e0245481. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481866>
6. Allen JC, Jr., Halaand B, Shirore RM, Jafar TH. Statistical analysis plan for management of hypertension and multiple risk factors to enhance cardiovascular health in Singapore: the SingHypertension pragmatic cluster randomized controlled trial. Trials 2021; 22:66. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468225>

## FH

1. Futema M, Ramaswami U, Tichy L *et al.* Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis 2021; 319:108-117. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33508743>
2. Vallejo-Vaz AJ, Packard CJ, Ference BA *et al.* LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. Atherosclerosis 2021; 320:1-9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497862>
3. Béland-Bonenfant S, Paquette M, Fantino M *et al.* Montreal-FH-SCORE Predicts Coronary Artery Calcium Score in Patients With Familial Hypercholesterolemia. CJC Open 2021; 3:41-47. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458631>
4. Drouin-Chartier JP, Tremblay AJ, Godbout D *et al.* Correlates of Coronary Artery Calcification Prevalence and Severity in Patients With Heterozygous Familial Hypercholesterolemia. CJC Open 2021; 3:62-70. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458634>
5. Jackson CL, Deng Y, Yao X *et al.* Proprotein convertase subtilisin/kexin type 9 inhibitor utilization and low-density lipoprotein-cholesterol control in familial hypercholesterolemia. J Clin Lipidol 2020. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33419720>

6. Vlad CE, Foia L, Florea L *et al.* Evaluation of cardiovascular risk factors in patients with familial hypercholesterolemia from the North-Eastern area of Romania. Lipids Health Dis 2021; 20:4. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33430859>

## Genetics

1. Vilar-Gomez E, Gawrieh S, Liang T *et al.* Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD. J Clin Lipidol 2020. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33454241>
2. Oni-Orisan A, Haldar T, Ranatunga DK *et al.* The impact of adjusting for baseline in pharmacogenomic genome-wide association studies of quantitative change. NPJ Genom Med 2020; 5:1. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33446660>
3. Srisawasdi P, Rodcharoen P, Vanavanan S *et al.* Association of CETP Gene Variants with Atherogenic Dyslipidemia Among Thai Patients Treated with Statin. Pharmacogenomics and personalized medicine 2021; 14:1-13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33447072>
4. Sun L, Pennells L, Kaptoge S *et al.* Polygenic risk scores in cardiovascular risk prediction: A cohort study and modelling analyses. PLoS Med 2021; 18:e1003498. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33444330>

## Guidelines

1. Jarrah MI, Ababneh MJ, Tawalbeh LI *et al.* Statin eligibility based on the ACC/AHA guidelines among Middle Eastern patients with diabetes mellitus presenting with acute myocardial infarction. Annals of medicine and surgery (2012) 2021; 61:148-154. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33425348>
2. Kuo TT, Huang YB, Hsieh CJ. Consumption and market share of cholesterol-lowering drugs in high-risk patients before and after the release of the 2013 ACC/AHA cholesterol guidelines: a retrospective observational study. BMJ Open 2020; 10:e036769. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33444173>
3. Dopheide JF, Adam L, Wiedmer S *et al.* Improved lipid target level attainment in patients with peripheral artery disease. Current vascular pharmacology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33430734>
4. Vogt A, Weingärtner O. [Management of dyslipidaemias: The New 2019 ESC/EAS-Guideline]. Deutsche medizinische Wochenschrift (1946) 2021; 146:75-84. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465803>
5. Handelsman Y, Jellinger PS, Guerin CK *et al.* Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm -

- 2020 Executive Summary. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2020; 26:1196-1224. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33471721>
6. Ray KK. Changing the paradigm for post-MI cholesterol lowering from intensive statin monotherapy towards intensive lipid-lowering regimens and individualized care. Eur Heart J 2021; 42:253-256. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33454778>
  7. Ravnskov U, Alabdulgader A, de Lorgeril M *et al*. The new European guidelines for prevention of cardiovascular disease are misleading. Expert Rev Clin Pharmacol 2021:1-6. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33416003>
  8. Cohen H, Durst R, Avizohar O *et al*. [UPDATED ISRAELI GUIDELINES FOR THE TREATMENT OF DYSLIPIDEMIA 2020]. Harefuah 2021; 160:38-44. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474877>
  9. Tong ST, Sabo RT, Hochheimer CJ *et al*. Uptake of Statin Guidelines to Prevent and Treat Cardiovascular Disease. Journal of the American Board of Family Medicine : JABFM 2021; 34:113-122. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33452089>
  10. Thomas AB, Choudhary DC, Raje A, Nagrik SS. Pharmacokinetics and Pharmacodynamic Herb-Drug Interaction of Piperine with Atorvastatin in Rats. Journal of chromatographic science 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33434916>
  11. Gard A, Lindahl B, Hadziosmanovic N, Baron T. Treatment and Prognosis of Myocardial Infarction Outside Cardiology Departments. Journal of clinical medicine 2020; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33396830>
  12. Lee JW, Lim H, Kim JH, Kim HS. Reassessment of Inclusion Criteria in the 2013 the American College of Cardiology and the American Heart Association Cholesterol Guidelines for Cardiovascular Disease Prevention. Journal of clinical neurology (Seoul, Korea) 2021; 17:86-95. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480203>
  13. Cornwell S, Curry K. Provider Adherence to Prescribing Guidelines for Statin Therapy. J Dr Nurs Pract 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468610>
  14. Fang HSA, Gao Q, Lee ML *et al*. LDL-cholesterol change and goal attainment following statin intensity titration among Asians in primary care: a retrospective cohort study. Lipids Health Dis 2021; 20:2. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33407522>
  15. Brown RE, Welsh P, Logue J. Systematic review of clinical guidelines for lipid lowering in the secondary prevention of cardiovascular disease events. Open heart 2020; 7. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33443127>

## LDL- related parameters

1. Jarrah MI, Ababneh MJ, Tawalbeh LI *et al.* Statin eligibility based on the ACC/AHA guidelines among Middle Eastern patients with diabetes mellitus presenting with acute myocardial infarction. Annals of medicine and surgery (2012) 2021; 61:148-154. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33425348>
2. Rubino J, MacDougall DE, Sterling LR *et al.* Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial. Atherosclerosis 2020. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514449>
3. Vallejo-Vaz AJ, Packard CJ, Ference BA *et al.* LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. Atherosclerosis 2021; 320:1-9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497862>
4. Li T, Zhang Y, Cong H. Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes. BMC Cardiovasc Disord 2021; 21:19. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33413096>
5. Kuo TT, Huang YB, Hsieh CJ. Consumption and market share of cholesterol-lowering drugs in high-risk patients before and after the release of the 2013 ACC/AHA cholesterol guidelines: a retrospective observational study. BMJ Open 2020; 10:e036769. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33444173>
6. Pirillo A, Catapano AL, Norata GD. Recent insights into low-density lipoprotein metabolism and therapy. Curr Opin Clin Nutr Metab Care 2020; Publish Ahead of Print. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33394716>
7. Dopheide JF, Adam L, Wiedmer S *et al.* Improved lipid target level attainment in patients with peripheral artery disease. Current vascular pharmacology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33430734>
8. Ray KK. Changing the paradigm for post-MI cholesterol lowering from intensive statin monotherapy towards intensive lipid-lowering regimens and individualized care. Eur Heart J 2021; 42:253-256. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33454778>
9. Jackson CL, Deng Y, Yao X *et al.* Proprotein convertase subtilisin/kexin type 9 inhibitor utilization and low-density lipoprotein-cholesterol control in familial hypercholesterolemia. J Clin Lipidol 2020. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33419720>
10. Vilar-Gomez E, Gawrieh S, Liang T *et al.* Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD. J Clin Lipidol 2020. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33454241>
11. Fang HSA, Gao Q, Lee ML *et al.* LDL-cholesterol change and goal attainment following statin intensity titration among Asians in primary care: a retrospective cohort

- study. Lipids Health Dis 2021;  
20:2. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33407522>
12. Oni-Orisan A, Haldar T, Ranatunga DK *et al.* The impact of adjusting for baseline in pharmacogenomic genome-wide association studies of quantitative change. NPJ Genom Med 2020; 5:1. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33446660>
  13. Srisawasdi P, Rodcharoen P, Vanavanan S *et al.* Association of CETP Gene Variants with Atherogenic Dyslipidemia Among Thai Patients Treated with Statin. Pharmacogenomics and personalized medicine 2021; 14:1-13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33447072>
  14. Kim JB, Song WH, Park JS *et al.* A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia. PLoS One 2021; 16:e0245481. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481866>

## Lifestyle

1. Jenkins DJA, Spence JD, Giovannucci EL *et al.* Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment: JACC Focus Seminar. J Am Coll Cardiol 2021; 77:423-436. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33509399>
2. Billinger SA, Whitaker AA, Morton A *et al.* Pilot Study to Characterize Middle Cerebral Artery Dynamic Response to an Acute Bout of Moderate Intensity Exercise at 3- and 6-Months Poststroke. J Am Heart Assoc 2021; 10:e017821. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496192>
3. Ye S, Matthan NR, Lamon-Fava S *et al.* Colon Transcriptome is Modified by a Dietary Pattern/Atorvastatin Interaction in the Ossabaw Pig. The Journal of nutritional biochemistry 2021:108570. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33429036>

## Meta-analyses

1. Wang J, Li X. Impact of statin use on the risk and prognosis of hepatocellular carcinoma: a meta-analysis. European journal of gastroenterology & hepatology 2021; Publish Ahead of Print. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33405428>
2. Sagris D, Ntaios G, Georgiopoulos G *et al.* Proprotein Convertase Subtilisin-Kexin Type 9 inhibitors and stroke prevention: A meta-analysis. Eur J Intern Med 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33419661>
3. Lai R, Ju J, Lin Q, Xu H. Coronary Artery Calcification Under Statin Therapy and Its Effect on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. Frontiers in cardiovascular medicine 2020; 7:600497. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33426001>



4. Lee MC, Peng TR, Lee CH *et al.* Statin use and depression risk: A systematic review and meta-analysis. Journal of affective disorders 2020; 282:308-315. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33421857>
5. Li R, Yuan M, Yu S *et al.* Effect of statins on the risk of recurrent venous thromboembolism: A systematic review and meta-analysis. Pharmacol Res 2021:105413. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33412275>
6. Pastori D, Baratta F, Di Rocco A *et al.* Statin use and mortality in atrial fibrillation: A systematic review and meta-analysis of 100,287 patients. Pharmacol Res 2021:105418. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33450384>
7. Onorato D, Pucci M, Carpena G *et al.* Protective Effects of Statins Administration in European and North American Patients Infected with COVID-19: A Meta-analysis. Seminars in thrombosis and hemostasis 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482680>

## Metabolic Syndrome - Diabetes

1. Werida R, Khairat I, Khedr NF. Effect of atorvastatin versus rosuvastatin on inflammatory biomarkers and LV function in type 2 diabetic patients with dyslipidemia. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2021; 135:111179. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33401219>
2. Yuan Y, Pan K, Mortimer J *et al.* Metabolic syndrome risk components and mortality after triple-negative breast cancer diagnosis in postmenopausal women in the Women's Health Initiative. Cancer 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476042>
3. Nelson AJ, Ardissino M, Haynes K *et al.* Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease. J Am Heart Assoc 2021; 10:e016835. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33432843>
4. Lu AD, Gunzburger E, Glorioso TJ *et al.* Impact of Longitudinal Virtual Primary Care on Diabetes Quality of Care. Journal of general internal medicine 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483815>
5. Mohamadin AM, Elberry AA, Abdel Gawad HS *et al.* Corrigendum to "Protective Effects of Simvastatin, a Lipid Lowering Agent, Against Oxidative Damage in Experimental Diabetic Rats". Journal of lipids 2020; 2020:4536827. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33414967>
6. Velarde GP, Choudhary N, Bravo-Jaimes K *et al.* Effect of atorvastatin on lipogenic, inflammatory and thrombogenic markers in women with the metabolic syndrome. Nutrition, metabolism, and cardiovascular diseases : NMCD 2020. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485731>

7. Marková I, Malínská H, Hüttl M *et al.* The combination of atorvastatin with silymarin enhances hypolipidemic, antioxidant and anti-inflammatory effects in a rat model of metabolic syndrome. Physiological research / Academia Scientiarum Bohemoslovaca 2021; 70. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33453720>

## New Treatments

1. Wang K, Yu C, Liu Y *et al.* Enhanced Antiatherosclerotic Efficacy of Statin-Loaded Reconstituted High-Density Lipoprotein via Ganglioside GM1 Modification. ACS biomaterials science & engineering 2018; 4:952-962. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33418777>
2. Delevry D, Gupta EK. Bempedoic acid: Review of a novel therapy in lipid management. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2021; 78:95-104. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33399194>
3. Zhang MM, Bahal R, Rasmussen TP *et al.* The growth of siRNA-based therapeutics: Updated clinical studies. Biochem Pharmacol 2021;114432. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513339>
4. Gutierrez LLP, Marques CV, Scomazzon SP *et al.* A-family anti-inflammatory cyclopentenone prostaglandins: A novel class of non-statin inhibitors of HMG-CoA reductase. Biochimie 2021; 182:37-50. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33412161>
5. Li T, Zhang Y, Cong H. Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes. BMC Cardiovasc Disord 2021; 21:19. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33413096>
6. Schwartz GG, Steg PG, Bhatt DL *et al.* Clinical Efficacy and Safety of Alirocumab after Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial. Circulation 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33438437>
7. Pirillo A, Catapano AL, Norata GD. Recent insights into low-density lipoprotein metabolism and therapy. Curr Opin Clin Nutr Metab Care 2020; Publish Ahead of Print. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33394716>
8. Sinning D, Landmesser U. [New Lipid-lowering Agents]. Deutsche medizinische Wochenschrift (1946) 2021; 146:92-101. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465805>
9. Sagris D, Ntaios G, Georgiopoulos G *et al.* Proprotein Convertase Subtilisin-Kexin Type 9 inhibitors and stroke prevention: A meta-analysis. Eur J Intern Med 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33419661>

10. Voutyritsa E, Damaskos C, Farmaki P *et al.* PCSK9 Antibody-based Treatment Strategies for Patients With Statin Intolerance. In Vivo 2021; 35:61-68. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33402450>
11. Sun J, Lepor NE, Cantón G *et al.* Serial magnetic resonance imaging detects a rapid reduction in plaque lipid content under PCSK9 inhibition with alirocumab. The international journal of cardiovascular imaging 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33392875>
12. Jackson CL, Deng Y, Yao X *et al.* Proprotein convertase subtilisin/kexin type 9 inhibitor utilization and low-density lipoprotein-cholesterol control in familial hypercholesterolemia. J Clin Lipidol 2020. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33419720>
13. Kotsopoulos N, Connolly MP, Li J. Estimating the public economic consequences of cardiovascular disease-attributable events and evolocumab treatment in Australia. Journal of medical economics 2021; 24:123-130. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464137>
14. Jatem E, Lima J, Montoro B *et al.* Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome. Kidney international reports 2021; 6:101-109. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33426389>

## Other

1. Navar AM, Wang TY, Li S *et al.* Patient-Perceived Versus Actual Risk of Cardiovascular Disease and Associated Willingness to Consider and Use Prevention Therapy. Circ Cardiovasc Qual Outcomes 2021; 14:e006548. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33435730>
2. Variation in statin prescribing across England. Drug and therapeutics bulletin 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483339>
3. Ravnskov U, Alabdulgader A, de Lorgeril M *et al.* The new European guidelines for prevention of cardiovascular disease are misleading. Expert Rev Clin Pharmacol 2021;1-6. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33416003>
4. Mitacchione G, Schiavone M, Curnis A *et al.* Impact of prior statin use on clinical outcomes in COVID-19 patients: data from tertiary referral hospitals during COVID-19 pandemic in Italy. J Clin Lipidol 2020. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33390341>
5. Li Y, Zhang Q, Di Z *et al.* The effect of ABCA1 gene DNA methylation on blood pressure levels in a Chinese hyperlipidemic population. J Hum Hypertens 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462393>

6. Inobhas A, Chansangpetch S, Manassakorn A *et al.* Effect of oral statin use on mitomycin-C augmented trabeculectomy outcomes. PLoS One 2021; 16:e0245429. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33449961>
7. Onorato D, Pucci M, Carpeno G *et al.* Protective Effects of Statins Administration in European and North American Patients Infected with COVID-19: A Meta-analysis. Seminars in thrombosis and hemostasis 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482680>

## PAD and statins

1. Rymer JA, Swaminathan RV, Aday AW *et al.* The Current Evidence for Lipid Management in Patients with Lower Extremity Peripheral Artery Disease: What Is the Therapeutic Target? Current cardiology reports 2021; 23:13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483872>
2. Dopheide JF, Adam L, Wiedmer S *et al.* Improved lipid target level attainment in patients with peripheral artery disease. Current vascular pharmacology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33430734>
3. Pulipati VP, Davidson MH. How I treat statin-associated side effects in an outpatient setting. Future cardiology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464124>

## Pleiotropic effects of statins

1. Zhou T, Moriyama Y, Ayukawa Y *et al.* Injectable Porous Bioresorbable Composite Containing Fluvastatin for Bone Augmentation. ACS biomaterials science & engineering 2019; 5:5422-5429. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464062>
2. Houshmand G, Pourasghar M, Shiran M *et al.* Simvastatin prevents morphine antinociceptive tolerance and withdrawal symptoms through antioxidative effect and nitric oxide pathway in mice. Behavioural brain research 2021; 402:113104. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33417990>
3. Rus I, Tertiş M, Barbălată C *et al.* An Electrochemical Strategy for the Simultaneous Detection of Doxorubicin and Simvastatin for Their Potential Use in the Treatment of Cancer. Biosensors (Basel) 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33401625>
4. Yang SY, Wang CC, Chen KD *et al.* Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma. BMC Cancer 2021; 21:70. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33446127>
5. Kura B, Kalocayova B, Szeiffova Bacova B *et al.* The effect of selected drugs on the mitigation of myocardial injury caused by gamma radiation. Canadian journal of

physiology and pharmacology 2021:1-

9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33438486>
6. Maneechotesuwan K, Kasetsinsombat K, Wongkajornsilp A, Barnes PJ. Role of autophagy in regulating interleukin-10 and the responses to corticosteroids and statins in asthma. Clin Exp Allergy 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33423318>
7. Shi Y, Wahle E, Du Q *et al.* Associations between Statin/Omega3 Usage and MRI-Based Radiomics Signatures in Prostate Cancer. Diagnostics (Basel, Switzerland) 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33430275>
8. Wang J, Li X. Impact of statin use on the risk and prognosis of hepatocellular carcinoma: a meta-analysis. European journal of gastroenterology & hepatology 2021; Publish Ahead of Print. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33405428>
9. Natalia ML, Patricia GL. Statins as adjuvants in the treatment of ovarian cancer: Controversy and misunderstanding. Eur J Pharmacol 2021; 896:173915. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513335>
10. Hamilton RJ, Ding K, Crook JM *et al.* The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy. European urology 2020. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33390282>
11. Chen CY, Wu WT, Wang YL, Liao KM. Statins for the Treatment of Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease. Frontiers in pharmacology 2020; 11:613761. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510638>
12. Blanc JF, Khemissa F, Bronowicki JP *et al.* Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis. Hepatology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33420951>
13. Rezvanian M, Ng SF, Alavi T, Ahmad W. In-vivo evaluation of Alginate-Pectin hydrogel film loaded with Simvastatin for diabetic wound healing in Streptozotocin-induced diabetic rats. International journal of biological macromolecules 2021; 171:308-319. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33421467>
14. Abdel-Qadir H, Bobrowski D, Zhou L *et al.* Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity Score-Matched Cohort Study. J Am Heart Assoc 2021:e018393. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33401953>
15. Katsuki S, Koga JI, Matoba T *et al.* Nanoparticle-Mediated Delivery of Pitavastatin to Monocytes/Macrophages Inhibits Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Apoe(-/-) Mice. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455994>
16. Shirakawa T, Fujisue K, Nakamura S *et al.* Dose-Dependent Inhibitory Effect of Rosuvastatin in Japanese Patients with Acute Myocardial Infarction on Serum Concentration of Matrix Metalloproteinases-INVITATION Trial. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33408315>

17. Tang B, Kang P, Zhu L *et al.* Simvastatin protects heart function and myocardial energy metabolism in pulmonary arterial hypertension induced right heart failure. J Bioenerg Biomembr 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33394312>
18. Fernandez KA, Allen P, Campbell M *et al.* Atorvastatin is associated with reduced cisplatin-induced hearing loss. J Clin Invest 2021; 131. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33393488>
19. Meyer N, Brodowski L, Richter K *et al.* Pravastatin Promotes Endothelial Colony-Forming Cell Function, Angiogenic Signaling and Protein Expression In Vitro. Journal of clinical medicine 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33419165>
20. Russo GI, Larganà G, Sebastianelli A *et al.* The Investigative Role of Statins in Ameliorating Lower Urinary Tract Symptoms (LUTS): A Systematic Review. Journal of clinical medicine 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499215>
21. Lochhead P, Khalili H, Sachs MC *et al.* Statin use and risk of inflammatory bowel diseases: authors' reply. Journal of Crohn's & colitis 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474560>
22. Yu WY, Hill ST, Chan ER *et al.* Computational drug repositioning identifies statins as a modifier of prognostic genetic expression signatures and metastatic behavior in melanoma. The Journal of investigative dermatology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33417917>
23. Bruiners N, Dutta NK, Guerrini V *et al.* The anti-tubercular activity of simvastatin is mediated by cholesterol-driven autophagy via the AMPK-mTORC1-TFEB axis. Journal of lipid research 2020; 61:1617-1628. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455707>
24. Teisseyre A, Uryga A, Michalak K. Statins as inhibitors of voltage-gated potassium channels Kv1.3 in cancer cells. J Mol Struct 2021; 1230:129905. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33437096>
25. Mansour BS, Salem NA, Kader GA *et al.* Protective effect of Rosuvastatin on Azithromycin induced cardiotoxicity in a rat model. Life sciences 2021; 269:119099. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476632>
26. Drugs for Migraine. The Medical letter on drugs and therapeutics 2020; 62:153-160. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33434187>
27. Ferro M, Marchioni M, Lucarelli G *et al.* Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicentre study. Minerva urologica e nefrologica = The Italian journal of urology and nephrology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33439571>
28. Lin CH, Chang CH, Tai CH *et al.* A Double-Blind, Randomized, Controlled Trial of Lovastatin in Early-Stage Parkinson's Disease. Movement disorders : official journal of

the Movement Disorder

Society 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33449392>

29. Lee J, Kreutzberger AJB, Odongo L *et al.* Ebola virus glycoprotein interacts with cholesterol to enhance membrane fusion and cell entry. Nat Struct Mol Biol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462517>
30. Shabanzadeh AP, Charish J, Tassew NG *et al.* Cholesterol synthesis inhibition promotes axonal regeneration in the injured central nervous system. Neurobiology of disease 2021:105259. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33434618>
31. Kawada T. Statin use and Parkinson's disease incidence. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33439391>
32. Osborne J, Friedman K, Runeckles K *et al.* Comparison Between Currently Recommended Long-Term Medical Management of Coronary Artery Aneurysms After Kawasaki Disease and Actual Reported Management in the Last Two Decades. Pediatr Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33439285>
33. Taymouri S, Ahmadi Z, Mirian M, Tavakoli N. Simvastatin nanosuspensions prepared using a combination of pH-sensitive and timed-release approaches for potential treatment of colorectal cancer. Pharmaceutical development and technology 2021:1-14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33430677>
34. Li R, Yuan M, Yu S *et al.* Effect of statins on the risk of recurrent venous thromboembolism: A systematic review and meta-analysis. Pharmacol Res 2021:105413. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33412275>
35. Chinaeke EE, Love BL, Magagnoli J *et al.* The Impact of Statin Use prior to intensive Care Unit (icu) Admission on critically Ill Patients with sepsis. Pharmacotherapy 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481279>
36. Atkins KM, Bitterman DS, Chaunzwa TL *et al.* Statin Use, Heart Radiation Dose, and Survival in Locally Advanced Lung Cancer. Pract Radiat Oncol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476841>
37. Mysore Y, Del Amo EM, Loukovaara S *et al.* Statins for the prevention of proliferative vitreoretinopathy: cellular responses in cultured cells and clinical statin concentrations in the vitreous. Scientific reports 2021; 11:980. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33441813>
38. Liu W, Wang M, Shen L *et al.* SHP2-mediated mitophagy boosted by lovastatin in neuronal cells alleviates parkinsonism in mice. Signal Transduct Target Ther 2021; 6:34. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514686>
39. Sorial AK, Anjum SA, Cook MJ *et al.* Statins, bone biology and revision arthroplasty: review of clinical and experimental evidence. Ther Adv Musculoskelet Dis 2020; 12:1759720x20966229. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33403020>



40. Li H, Wang Y, Liu J *et al.* Endothelial Klf2-Foxp1-TGF $\beta$  signal mediates the inhibitory effects of simvastatin on maladaptive cardiac remodeling. Theranostics 2021; 11:1609-1625. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33408770>
41. Yang Y, Yang LY, Salayandia VM *et al.* Treatment with Atorvastatin During Vascular Remodeling Promotes Pericyte-Mediated Blood-Brain Barrier Maturation Following Ischemic Stroke. Translational stroke research 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33423214>
42. Huynh LM, Keit E, Schuller AA *et al.* Impact of statin use on overall and time to biochemical failure following radical prostatectomy or radiation therapy. World J Urol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502557>

## Primary Prevention

1. Zhou Z, Jose K, Curtis AJ *et al.* Older participant perspectives on permanent study drug discontinuation in an ongoing primary prevention trial of statins. Eur J Clin Pharmacol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33410972>
2. Venkataraman P, Kawakami H, Huynh Q *et al.* Cost-Effectiveness of Coronary Artery Calcium Scoring in People With a Family History of Coronary Disease. JACC. Cardiovascular imaging 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33454262>
3. Rasmussen P, Yandrapalli S, Aronow W. Statin therapy for primary cardiovascular prevention in older adults over 75 years. Kardiol Pol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33427435>
4. Jung HH. Statin use and outcome risks according to predicted CVD risk in Korea: A retrospective cohort study. PLoS One 2021; 16:e0245609. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33450746>

## Registry data

1. Trivedi LU, Femnou Mbuntum L, Halm EA, Mansi I. Is Statin Use Associated With Risk of Thyroid Diseases? Results of a Retrospective Cohort Study. The Annals of pharmacotherapy 2021:1060028020986552. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33412925>
2. Li X, Gu F, Ding J *et al.* The predictors and prognosis for unexpected reocclusion after mechanical thrombectomy: a meta-analysis. Annals of translational medicine 2020; 8:1566. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33437765>
3. Mahtta D, Lee MT, Ramsey DJ *et al.* Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans with

- premaTure Atherosclerosis) Registry7. Cardiovasc Drugs Ther 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33400053>
4. Chen CY, Wu WT, Wang YL, Liao KM. Statins for the Treatment of Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease. Frontiers in pharmacology 2020; 11:613761. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510638>
  5. Spencer-Bonilla G, Chung S, Sarraju A *et al*. Statin Use in Older Adults with Stable Atherosclerotic Cardiovascular Disease. J Am Geriatr Soc 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33410499>
  6. Mitacchione G, Schiavone M, Curnis A *et al*. Impact of prior statin use on clinical outcomes in COVID-19 patients: data from tertiary referral hospitals during COVID-19 pandemic in Italy. J Clin Lipidol 2020. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33390341>
  7. Majd Z, Mohan A, Paranjpe R, Abughosh SM. Identifying adherent patients to newly initiated statins using previous adherence to chronic medications. Journal of managed care & specialty pharmacy 2021; 27:186-197. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506725>
  8. Gardener H, Rundek T, Lichtman J *et al*. Adherence to Acute Care Measures Affects Mortality in Patients with Ischemic Stroke: The Florida Stroke Registry. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2021; 30:105586. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33412397>
  9. Ferro M, Marchioni M, Lucarelli G *et al*. Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicentre study. Minerva urologica e nefrologica = The Italian journal of urology and nephrology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33439571>
  10. Bruning T, Al-Khaled M. Do statins reduce the mortality rate in stroke patients treated with systemic thrombolysis in a 5-year. Neural regeneration research 2021; 16:1807-1812. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510087>
  11. Sun L, Pennells L, Kaptoge S *et al*. Polygenic risk scores in cardiovascular risk prediction: A cohort study and modelling analyses. PLoS Med 2021; 18:e1003498. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33444330>
  12. Inobhas A, Chansangpetch S, Manassakorn A *et al*. Effect of oral statin use on mitomycin-C augmented trabeculectomy outcomes. PLoS One 2021; 16:e0245429. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33449961>
  13. Kuo FY, Huang WC, Tang PL *et al*. Impact of statin on long-term outcome among patients with end-stage renal disease with acute myocardial infarction (AMI): a nationwide case-control study. Postgraduate medical journal 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33452152>

14. Lin CK, Chen PY, Wu YY *et al.* Adjunctive Statin Therapy Reduces Mortality After Acute Hemorrhagic Stroke. Risk Manag Healthc Policy 2021; 14:177-183. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488130>

## Renal Disease

1. Al-Doaiss A, Jarrar Y, Shati A *et al.* Renal Alterations Induced by Chronic Exposure to Therapeutic Doses of Antihypercholesteremic Atorvastatin. Endocrine, metabolic & immune disorders drug targets 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33413070>
2. Silva-Almodóvar A, Hackim E, Wolk H, Nahata MC. Potentially Inappropriately Prescribed Medications Among Medicare Medication Therapy Management Eligible Patients with Chronic Kidney Disease: an Observational Analysis. Journal of general internal medicine 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506400>
3. Jatem E, Lima J, Montoro B *et al.* Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome. Kidney international reports 2021; 6:101-109. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33426389>
4. Kuo FY, Huang WC, Tang PL *et al.* Impact of statin on long-term outcome among patients with end-stage renal disease with acute myocardial infarction (AMI): a nationwide case-control study. Postgraduate medical journal 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33452152>

## Reviews

1. Delevry D, Gupta EK. Bempedoic acid: Review of a novel therapy in lipid management. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2021; 78:95-104. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33399194>
2. Guo D, Meng Z, He F *et al.* Infection-Induced Rhabdomyolysis in an Elderly Patient on Stable Rosuvastatin Therapy: A Case Report and Review of the Literature. American journal of therapeutics 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33443867>
3. Zhang MM, Bahal R, Rasmussen TP *et al.* The growth of siRNA-based therapeutics: Updated clinical studies. Biochem Pharmacol 2021:114432. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513339>
4. Yun HJ, Ding Y. How to remove those bloody collections: Nonsurgical treatment options for chronic subdural hematoma. Brain circulation 2020; 6:254-259. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506148>

5. Libby P. Inflammation in Atherosclerosis-No Longer a Theory. Clinical chemistry 2021; 67:131-142. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33393629>
6. Kanukula R, Salam A, Rodgers A, Kamel B. Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults. Clinical pharmacokinetics 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33428168>
7. Hussain A, Al Rifai M, Mahtta D *et al.* Highlights from Studies Presented at the American Heart Association Scientific Session 2020: Navigating New Roads in Prevention. Curr Atheroscler Rep 2021; 23:4. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33392871>
8. Rymer JA, Swaminathan RV, Aday AW *et al.* The Current Evidence for Lipid Management in Patients with Lower Extremity Peripheral Artery Disease: What Is the Therapeutic Target? Current cardiology reports 2021; 23:13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483872>
9. Balasubramanian R, Maideen NMP. HMG-CoA reductase inhibitors (Statins) and their Drug Interactions involving CYP enzymes, P-glycoprotein and OATP Transporters - An Overview. Current drug metabolism 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459228>
10. Reyes-Soffer G. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease risk: current status and treatments. Current opinion in endocrinology, diabetes, and obesity 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481422>
11. Adamstein NH, MacFadyen JG, Rose LM *et al.* The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. Eur Heart J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33417682>
12. Pulipati VP, Davidson MH. How I treat statin-associated side effects in an outpatient setting. Future cardiology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464124>
13. Russo GI, Larganà G, Sebastianelli A *et al.* The Investigative Role of Statins in Ameliorating Lower Urinary Tract Symptoms (LUTS): A Systematic Review. Journal of clinical medicine 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33499215>
14. Khan MS, Ishaq M, Ayub MT *et al.* The Novelty of Icosapent Ethyl in the Management of Hypertriglyceridemia and Alleviating Cardiovascular Risk. Journal of lipids 2021; 2021:6696915. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33505729>
15. Kawada T. Statin use and Parkinson's disease incidence. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33439391>
16. Brown RE, Welsh P, Logue J. Systematic review of clinical guidelines for lipid lowering in the secondary prevention of cardiovascular disease events. Open heart 2020; 7. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33443127>

17. Sorial AK, Anjum SA, Cook MJ *et al.* Statins, bone biology and revision arthroplasty: review of clinical and experimental evidence. Ther Adv Musculoskelet Dis 2020; 12:1759720x20966229. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33403020>

## Safety and side effects

1. Roan JN, Lin WH, Tsai MT *et al.* Rosuvastatin Failed to Improve Arteriovenous Fistula Patency for Hemodialysis in Diabetic Patients - A Randomized Clinical Trial. Acta Cardiologica Sinica 2021; 37:18-29. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488024>
2. Guo D, Meng Z, He F *et al.* Infection-Induced Rhabdomyolysis in an Elderly Patient on Stable Rosuvastatin Therapy: A Case Report and Review of the Literature. American journal of therapeutics 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33443867>
3. Famularo G, Sarrecchia C. Atorvastatin-Associated Gynecomastia. The Annals of pharmacotherapy 2021:1060028021988994. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472378>
4. Trivedi LU, Femnou Mbuntum L, Halm EA, Mansi I. Is Statin Use Associated With Risk of Thyroid Diseases? Results of a Retrospective Cohort Study. The Annals of pharmacotherapy 2021:1060028020986552. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33412925>
5. Susekov AV, Korol LA, Watts GF. Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance. Cardiovasc Drugs Ther 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502687>
6. Kanukula R, Salam A, Rodgers A, Kamel B. Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults. Clinical pharmacokinetics 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33428168>
7. Shawish MI, Bagheri B, Musini VM *et al.* Effect of atorvastatin on testosterone levels. The Cochrane database of systematic reviews 2021; 1:Cd013211. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482034>
8. Lempel M, Molla E. Treatment of Statin-Induced Necrotizing Autoimmune Myopathy With Glucocorticoid Monotherapy. Cureus 2020; 12:e12086. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33489504>
9. Nguyen S, Alexander SA, Apenteng S, Castiglione A. Statin-Associated Necrotizing Myopathy: A Feared Complication. Cureus 2020; 12:e11689. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33391923>
10. Balasubramanian R, Maideen NMP. HMG-CoA reductase inhibitors (Statins) and their Drug Interactions involving CYP enzymes, P-glycoprotein and OATP Transporters - An Overview. Current drug metabolism 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459228>

11. Keni R, Sekhar A, Gourishetti K *et al.* Role of Statins in New-onset Diabetes Mellitus: The Underlying Cause, Mechanisms Involved, and Strategies to Combat. Current drug targets 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33494673>
12. Larsen JV, Martinsen MH, Mortensen MB *et al.* Contemporary lipid clinic and achievements in low-density lipoprotein-cholesterol reductions in very high-risk patients. Dan Med J 2020; 68. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463509>
13. Al-Doaiss A, Jarrar Y, Shati A *et al.* Renal Alterations Induced by Chronic Exposure to Therapeutic Doses of Antihypercholesteremic Atorvastatin. Endocrine, metabolic & immune disorders drug targets 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33413070>
14. Zhou Z, Jose K, Curtis AJ *et al.* Older participant perspectives on permanent study drug discontinuation in an ongoing primary prevention trial of statins. Eur J Clin Pharmacol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33410972>
15. Hamilton RJ, Ding K, Crook JM *et al.* The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy. European urology 2020. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33390282>
16. Voutyritsa E, Damaskos C, Farmaki P *et al.* PCSK9 Antibody-based Treatment Strategies for Patients With Statin Intolerance. In Vivo 2021; 35:61-68. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33402450>
17. Avram VF, Chamkha I, Åsander-Frostner E *et al.* Cell-Permeable Succinate Rescues Mitochondrial Respiration in Cellular Models of Statin Toxicity. Int J Mol Sci 2021; 22. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33401621>
18. Lee MC, Peng TR, Lee CH *et al.* Statin use and depression risk: A systematic review and meta-analysis. Journal of affective disorders 2020; 282:308-315. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33421857>
19. Wei G, Xue L, Zhu Y *et al.* Differences in susceptibility of HT-29 and A549 cells to statin-induced toxicity: An investigation using high content screening. Journal of biochemical and molecular toxicology 2021:e22699. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33398916>
20. Mollazadeh H, Tavana E, Fanni G *et al.* Effects of statins on mitochondrial pathways. Journal of cachexia, sarcopenia and muscle 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33511728>
21. Silva-Almodóvar A, Hackim E, Wolk H, Nahata MC. Potentially Inappropriately Prescribed Medications Among Medicare Medication Therapy Management Eligible Patients with Chronic Kidney Disease: an Observational Analysis. Journal of general internal medicine 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506400>
22. Ajima H, Kai Y, Fujimaki J *et al.* Effects of fenofibrate and its combination with lovastatin on the expression of genes involved in skeletal muscle atrophy, including

- FoxO1 and its targets. The Journal of toxicological sciences 2021; 46:11-24. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33408297>
23. Robinson JG. The neuropsychology of statin intolerance. Nat Rev Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33408360>
  24. Inobhas A, Chansangpetch S, Manassakorn A *et al.* Effect of oral statin use on mitomycin-C augmented trabeculectomy outcomes. PLoS One 2021; 16:e0245429. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33449961>
  25. Kim JB, Song WH, Park JS *et al.* A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia. PLoS One 2021; 16:e0245481. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481866>
  26. van der Ploeg MA, Poortvliet RKE, van Blijswijk SCE *et al.* Correction: Statin Use and Self-Reported Hindering Muscle Complaints in Older Persons: A Population Based Study. PLoS One 2021; 16:e0245997. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481919>
  27. Huda SA, Yadava S, Kahlown S *et al.* Statin-induced necrotizing autoimmune myopathy. Proceedings (Baylor University. Medical Center) 2020; 34:185-186. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456195>
  28. Lim D, Landon-Cardinal O, Ellezam B *et al.* Statin-associated anti-HMGCR immune-mediated necrotizing myopathy with dermatomyositis-like features: A case report. SAGE Open Med Case Rep 2020; 8:2050313x20984120. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33447390>
  29. Christiansen LB, Dohlmann TL, Ludvigsen TP *et al.* Atorvastatin impairs liver mitochondrial function in obese Göttingen Minipigs but heart and skeletal muscle are not affected. Scientific reports 2021; 11:2167. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500513>
  30. Huynh LM, Keit E, Schuller AA *et al.* Impact of statin use on overall and time to biochemical failure following radical prostatectomy or radiation therapy. World J Urol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502557>

## Stroke and CNS

1. Khazaei M, Khosravi M, Mazaheri S *et al.* The effect of atorvastatin on the common carotid artery intima-media thickness in patients with ischemic stroke. Acta clinica Croatica 2020; 59:223-226. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456108>
2. Bergeron S, Barus R, Leboullenger C *et al.* Beneficial effects of atorvastatin on sex-specific cognitive impairment induced by a cerebral microhaemorrhage in a murine model. Br J Pharmacol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502755>



3. Yun HJ, Ding Y. How to remove those bloody collections: Nonsurgical treatment options for chronic subdural hematoma. Brain circulation 2020; 6:254-259. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33506148>
4. Sagris D, Ntaios G, Georgiopoulos G *et al.* Proprotein Convertase Subtilisin-Kexin Type 9 inhibitors and stroke prevention: A meta-analysis. Eur J Intern Med 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33419661>
5. Billinger SA, Whitaker AA, Morton A *et al.* Pilot Study to Characterize Middle Cerebral Artery Dynamic Response to an Acute Bout of Moderate Intensity Exercise at 3- and 6-Months Poststroke. J Am Heart Assoc 2021; 10:e017821. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33496192>
6. Uematsu M, Nakamura T, Horikoshi T *et al.* Echolucency of carotid plaque is useful for selecting high-risk patients with chronic coronary artery disease who benefit from intensive lipid-lowering therapy. J Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33500186>
7. Gardener H, Rundek T, Lichtman J *et al.* Adherence to Acute Care Measures Affects Mortality in Patients with Ischemic Stroke: The Florida Stroke Registry. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2021; 30:105586. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33412397>
8. Lin CH, Chang CH, Tai CH *et al.* A Double-Blind, Randomized, Controlled Trial of Lovastatin in Early-Stage Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33449392>
9. Bruning T, Al-Khaled M. Do statins reduce the mortality rate in stroke patients treated with systemic thrombolysis in a 5-year. Neural regeneration research 2021; 16:1807-1812. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33510087>
10. Shabanzadeh AP, Charish J, Tassew NG *et al.* Cholesterol synthesis inhibition promotes axonal regeneration in the injured central nervous system. Neurobiology of disease 2021:105259. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33434618>
11. Lin CK, Chen PY, Wu YY *et al.* Adjunctive Statin Therapy Reduces Mortality After Acute Hemorrhagic Stroke. Risk Manag Healthc Policy 2021; 14:177-183. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33488130>
12. Liu W, Wang M, Shen L *et al.* SHP2-mediated mitophagy boosted by lovastatin in neuronal cells alleviates parkinsonism in mice. Signal Transduct Target Ther 2021; 6:34. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514686>
13. Yang Y, Yang LY, Salayandia VM *et al.* Treatment with Atorvastatin During Vascular Remodeling Promotes Pericyte-Mediated Blood-Brain Barrier Maturation Following Ischemic Stroke. Translational stroke research 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33423214>

## Triglycerides/HDL

1. Wang K, Yu C, Liu Y *et al.* Enhanced Antiatherosclerotic Efficacy of Statin-Loaded Reconstituted High-Density Lipoprotein via Ganglioside GM1 Modification. ACS biomaterials science & engineering 2018; 4:952-962. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33418777>
2. Reyes-Soffer G. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease risk: current status and treatments. Current opinion in endocrinology, diabetes, and obesity 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481422>
3. Omote K, Yokota I, Nagai T *et al.* High-Density Lipoprotein Cholesterol and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Statins: An Observation from the REAL-CAD Study. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33431716>

## Trials

1. Khazaei M, Khosravi M, Mazaheri S *et al.* The effect of atorvastatin on the common carotid artery intima-media thickness in patients with ischemic stroke. Acta clinica Croatica 2020; 59:223-226. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456108>
2. Ambrosy AP, Malik UI, Thomas RC *et al.* Rationale and Design of the Pragmatic Randomized Trial of Icosapent Ethyl for High Cardiovascular Risk Adults (MITIGATE). Am Heart J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33516752>
3. Nicholls SJ, Lincoff AM, Bays HE *et al.* Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J 2020. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33470195>
4. Rubino J, MacDougall DE, Sterling LR *et al.* Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial. Atherosclerosis 2020. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33514449>
5. Vallejo-Vaz AJ, Packard CJ, Ference BA *et al.* LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. Atherosclerosis 2021; 320:1-9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33497862>
6. Werida R, Khairat I, Khedr NF. Effect of atorvastatin versus rosuvastatin on inflammatory biomarkers and LV function in type 2 diabetic patients with dyslipidemia. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2021; 135:111179. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33401219>

7. Susekov AV, Korol LA, Watts GF. Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance. Cardiovasc Drugs Ther 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502687>
8. Schwartz GG, Steg PG, Bhatt DL *et al.* Clinical Efficacy and Safety of Alirocumab after Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial. Circulation 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33438437>
9. Umrani S, Jamshed W, Rizwan A. Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Markers in Acute Coronary Syndrome. Cureus 2020; 12:e11760. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33409009>
10. Hussain A, Al Rifai M, Mahtta D *et al.* Highlights from Studies Presented at the American Heart Association Scientific Session 2020: Navigating New Roads in Prevention. Curr Atheroscler Rep 2021; 23:4. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33392871>
11. Blanc JF, Khemissa F, Bronowicki JP *et al.* Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis. Hepatol Int 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33420951>
12. Voutyritsa E, Damaskos C, Farmaki P *et al.* PCSK9 Antibody-based Treatment Strategies for Patients With Statin Intolerance. In Vivo 2021; 35:61-68. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33402450>
13. Sun J, Lepor NE, Cantón G *et al.* Serial magnetic resonance imaging detects a rapid reduction in plaque lipid content under PCSK9 inhibition with alirocumab. The international journal of cardiovascular imaging 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33392875>
14. Omote K, Yokota I, Nagai T *et al.* High-Density Lipoprotein Cholesterol and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Statins: An Observation from the REAL-CAD Study. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33431716>
15. Shirakawa T, Fujisue K, Nakamura S *et al.* Dose-Dependent Inhibitory Effect of Rosuvastatin in Japanese Patients with Acute Myocardial Infarction on Serum Concentration of Matrix Metalloproteinases-INVITATION Trial. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33408315>
16. Lin CH, Chang CH, Tai CH *et al.* A Double-Blind, Randomized, Controlled Trial of Lovastatin in Early-Stage Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33449392>
17. Oni-Orisan A, Haldar T, Ranatunga DK *et al.* The impact of adjusting for baseline in pharmacogenomic genome-wide association studies of quantitative change. NPJ Genom Med 2020; 5:1. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33446660>

18. Inobhas A, Chansangpetch S, Manassakorn A *et al.* Effect of oral statin use on mitomycin-C augmented trabeculectomy outcomes. PLoS One 2021; 16:e0245429. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33449961>
19. Kim JB, Song WH, Park JS *et al.* A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia. PLoS One 2021; 16:e0245481. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481866>
20. Mysore Y, Del Amo EM, Loukovaara S *et al.* Statins for the prevention of proliferative vitreoretinopathy: cellular responses in cultured cells and clinical statin concentrations in the vitreous. Scientific reports 2021; 11:980. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33441813>
21. Allen JC, Jr., Halaand B, Shirore RM, Jafar TH. Statistical analysis plan for management of hypertension and multiple risk factors to enhance cardiovascular health in Singapore: the SingHypertension pragmatic cluster randomized controlled trial. Trials 2021; 22:66. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468225>
22. Huynh LM, Keit E, Schuller AA *et al.* Impact of statin use on overall and time to biochemical failure following radical prostatectomy or radiation therapy. World J Urol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502557>

## Women and elderly

1. Bergeron S, Barus R, Leboullenger C *et al.* Beneficial effects of atorvastatin on sex-specific cognitive impairment induced by a cerebral microhaemorrhage in a murine model. Br J Pharmacol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33502755>
2. Yuan Y, Pan K, Mortimer J *et al.* Metabolic syndrome risk components and mortality after triple-negative breast cancer diagnosis in postmenopausal women in the Women's Health Initiative. Cancer 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476042>
3. Zhou Z, Jose K, Curtis AJ *et al.* Older participant perspectives on permanent study drug discontinuation in an ongoing primary prevention trial of statins. Eur J Clin Pharmacol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33410972>
4. Natalia ML, Patricia GL. Statins as adjuvants in the treatment of ovarian cancer: Controversy and misunderstanding. Eur J Pharmacol 2021; 896:173915. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33513335>
5. Spencer-Bonilla G, Chung S, Sarraju A *et al.* Statin Use in Older Adults with Stable Atherosclerotic Cardiovascular Disease. J Am Geriatr Soc 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33410499>
6. Rasmussen P, Yandrapalli S, Aronow W. Statin therapy for primary cardiovascular prevention in older adults over 75 years. Kardiol Pol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33427435>

7. Velarde GP, Choudhary N, Bravo-Jaimes K *et al.* Effect of atorvastatin on lipogenic, inflammatory and thrombogenic markers in women with the metabolic syndrome. Nutrition, metabolism, and cardiovascular diseases : NMCD 2020. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485731>
8. van der Ploeg MA, Poortvliet RKE, van Blijswijk SCE *et al.* Correction: Statin Use and Self-Reported Hindering Muscle Complaints in Older Persons: A Population Based Study. PLoS One 2021; 16:e0245997. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481919>

---

This activity is supported by an educational grant from Viatrix.  
© P.J. Lansberg